Focus: Inotiv is a publicly-traded contract research organization (CRO) and scientific instruments provider specializing in preclinical and clinical lab services across neurology, ophthalmology, immunology, gastroenterology, and infectious diseases. The company operates at $572M annual revenue scale with a heavy R&D hiring footprint.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Stable — net +2 jobs in 30d
41 added, 39 removed. Backfill posture.
Inotiv offers research-heavy roles and public-company structure, but acute bankruptcy risk and consecutive years of losses make this a high-risk career move unless you have strong risk tolerance or short-term contract appetite.
Help build intelligence for Inotiv
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Inotiv's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Inotiv, Inc. Financial Statements – OTC:NOTVQ - TradingView
Inotiv, Inc. Financial Statements – OTC:NOTVQ TradingView
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Bankruptcy status is an acute red flag; career prospects depend on emergence timeline and buyer interest.
Recent peer-reviewed publications with author affiliations at this company
Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data.
Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma.
Showing 5 of 10 publications